Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTM-005
- Development stage
- Preclinical
- Lead developer
- Neumentum
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NTM-005 is an oral small molecule new chemical entity (NCE) being developed by Neumentum as a non-opioid treatment for acute pain, chronic pain, and inflammation. Designed as an analogue of acetaminophen (APAP), it is intended to serve as a safer alternative to traditional analgesics by potentially avoiding the hepatotoxicity associated with high-dose APAP and the addiction risks of opioids. The compound is currently in the IND-enabling stage of development. While its specific molecular target has not been publicly disclosed, it represents a key part of Neumentum's strategy to develop novel, non-addictive pain management therapies.
Beyond the preview
Go deeper on NTM-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTM-005.